Welcome to our dedicated page for Globus Med news (Ticker: GMED), a resource for investors and traders seeking the latest updates and insights on Globus Med stock.
Globus Medical, Inc. (NYSE: GMED) is a global musculoskeletal company in the surgical and medical instrument manufacturing industry. The GMED news page on Stock Titan aggregates coverage focused on the company’s musculoskeletal solutions, enabling technologies, and corporate developments that matter to investors and healthcare professionals.
News about Globus Medical often centers on quarterly and annual financial results, where the company reports worldwide net sales, U.S. and international performance, and non-GAAP metrics such as adjusted EBITDA, non-GAAP net income, and non-GAAP diluted earnings per share. These releases also discuss trends in its U.S. Spine business, contributions from acquisitions such as NuVasive and Nevro, and updates to revenue and earnings guidance.
Product and technology announcements are another key news category. Globus Medical has highlighted launches like the ANTHEM™ Elbow Fracture System within its trauma portfolio and additions to its Power Portfolio, including the DuraPro™ oscillating system with navigation and the Verzera™ high-speed drill system, which integrate with platforms such as ExcelsiusGPS™ and ExcelsiusHub™. These updates provide insight into the company’s efforts to advance spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies.
Investors can also follow corporate and legal developments, including leadership transitions at the executive level, share repurchase authorizations, and patent litigation outcomes related to expandable spinal fusion implants and other technologies. Earnings call schedules and webcast details are regularly announced, giving context on how management views business performance and strategic priorities.
By monitoring GMED news, readers can track how Globus Medical’s financial results, product pipeline, acquisitions, and intellectual property strategy evolve over time. Bookmark this page to access an organized stream of company-specific headlines and updates.
Globus Medical (NYSE:GMED) will announce its second-quarter financial results for the period ending June 30, 2022, after market close on August 4, 2022. Investors can access the release on their website. A teleconference will be held the same day at 4:30 p.m. Eastern Time to discuss the performance with stakeholders. Interested participants can join via a webcast or telephone by pre-registering for access. The audio archive will be available post-call. Globus Medical specializes in musculoskeletal solutions and was founded in 2003.
Globus Medical (NYSE: GMED) announced the successful first surgeries using the Excelsius3D™ imaging platform, enhancing its existing ExcelsiusGPS® robotic navigation system. Surgeons from various hospitals performed these surgeries, highlighting the system's capabilities for minimally invasive procedures and improved surgical outcomes. The Excelsius3D™ provides a streamlined navigation workflow, offers multiple imaging modes, and reduces radiation exposure. This technology is now commercially available in the US, aiming to elevate patient care in spinal surgeries.
Globus Medical (NYSE: GMED) reported Q1 2022 financial results, with worldwide net sales of $230.5 million, a 1.4% year-over-year increase. GAAP net income was $38.1 million, reflecting a 16.0% decrease from the previous year, attributed to higher product development and marketing expenses. Diluted EPS stood at $0.37, down 13.1% from $0.44. The company reaffirmed its 2022 guidance, targeting $1.025 billion in net sales. Notably, U.S. Spine sales showed recovery, with record performance in March.
Globus Medical (NYSE:GMED) is set to release its financial results for Q1 ended March 31, 2022, on May 10, 2022, after market close. Investors can access the release on the company’s website, where a teleconference will follow at 4:30 p.m. ET to discuss performance with the investment community. Interested parties can join the call via phone or access it online. The company specializes in musculoskeletal solutions, aiming to enhance surgical outcomes.
Globus Medical, Inc. (NYSE: GMED) announced the resignation of CEO Dave Demski after nearly 20 years, effective immediately. Daniel T. Scavilla, previously Chief Financial Officer, has been named the new CEO. The company anticipates first-quarter 2022 sales of approximately $230.5 million, reflecting a 1.4% year-over-year increase. Globus reaffirmed its full-year guidance, expecting net sales of $1.025 billion and non-GAAP diluted earnings per share of $2.10 for 2022. The financial results for Q1 2022 will be announced on May 10, 2022.
Globus Medical (NYSE: GMED) announced an expansion of its share repurchase program by authorizing an additional $200 million for buying back common stock. This increase brings the total available for repurchase to over $295 million, combining with the existing $95.3 million authorized in March 2020. The Board's decision reflects confidence in the company's long-term growth and financial stability. The repurchase strategy will prioritize market conditions and company performance while ensuring strategic investments align with sustaining growth.
Globus Medical, Inc. (NYSE: GMED) reported strong financial results for Q4 and full-year 2021. Q4 net sales reached $250.0 million, up 7.1% year-over-year. GAAP net income was $15.1 million, a 71.5% decrease from Q4 2020, primarily due to R&D acquisition costs. Full-year net sales totaled $958.1 million, an increase of 21.4%. Non-GAAP diluted EPS for 2021 was $2.04. The company anticipates 2022 sales of $1.025 billion with EPS of $2.10.
Globus Medical (NYSE:GMED) is set to announce its financial results for the fourth quarter and full year ended December 31, 2021, on February 17, 2022, after market close. The release will be available on the company’s website. Following this, a teleconference will be held at 4:30 p.m. ET to discuss the results with investors. No passcode is required for participation, and the call will be accessible via the website for those wishing to listen in without asking questions.
Globus Medical, Inc. (NYSE: GMED) reported its financial results for Q3 2021, highlighting worldwide net sales of $229.7 million, a 6.3% increase year-over-year. GAAP net income was $47.2 million, or 20.6% of sales, reflecting a 6.8% rise. Diluted EPS stood at $0.45 GAAP and $0.50 non-GAAP. Notably, U.S. sales rose 8.8%, while international sales declined 7.2%. The company confirmed full-year guidance of $950 million in net sales and $2.00 in non-GAAP EPS. Cash reserves total $985 million, maintaining a debt-free status.
On October 19, 2021, Globus Medical (NYSE:GMED) announced the launch of its ANTHEM® Mini Fragment Fracture System at the Orthopaedic Trauma Association meeting in Fort Worth, Texas. This innovative system is designed for the fixation of small bones and non-load-bearing stabilization of long bones. The system includes titanium and stainless-steel implants with various plate styles and advanced polyaxial locking technology. The initiative aligns with the growing trend among surgeons to use mini fragment plates for complex fractures, enhancing procedural efficiency.